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The goal of this study was to analyze and compare the clinical and radiological outcome in patients after implantation of the nonresorbable oxyhydroxyapatite glass-ceramic and Beta-Tricalcium phosphate used to fill the defects of long bones after curettage of bone cysts.
Materials and methods

Patients
This retrospective study was approved by the local research ethics committee, and all participants gave their written, informed consent. We evaluated 39 consecutive patients who fulfilled the following inclusion criteria: (i) histologically confirmed unicameral bone cyst, (ii) treatment by curettage of the lesion and implantation of glass-ceramic or betatricalcium phosphate, (iii) follow-up after at least 24 months to confirm a static radiographic outcome without recurrence of benign bone lesion. There were 28 male and 11 female patients. The age of the 21 patients with the implanted nonresorbable glass-ceramic at the time of surgery was 4-44 years with an average age of 15 years. The age of the 18 patients with implanted beta-tricalcium phosphate at the time of surgery was 7-30 years with an average age of 14 years. The unicameral bone cysts were located in the humerus (16 patients) , femur (13) , fibula (4), tibia (2), calcaneus (2), ulna (1), and iliac bone (1). All patients had curettage of the cyst and filling of the resulting bone defect with glass-ceramic (15 male and 6 female) or tricalcium phosphate (13 male and 5 female). Cortical fenestration was carried out using an osteotome and the soft tissue membrane was removed by a curette. After the filling of the bone defect with glass-ceramic or tricalcium phosphate, the cortical window was replaced. Internal fixation was employed in four patients because a pathological fracture occurred in 3 cases and an impending fracture was in 1 patient. Splints or bandages were used postoperatively for patients judged to be at risk of pathological fracture. Full weight bearing was allowed after 8-12 weeks. The patients were scheduled for follow-up evaluations which included clinical and radiographic examinations at 4-6, 10-14 weeks, 6 and 12 months intervals. Thereafter they were seen yearly.
Filling
A bioactive glass-ceramic material with wollastonite, oxyhydroxyapatite, residual glass phase, and whitlockite at a ratio of 45-30-20-5% (BAS-0, Lasak Ltd., Prague, Czech Republic) was used. The apatite-wollastonite glass-ceramic was dense with a porosity of less than 0.5%. The sintering temperature was 1200°C, the bending strength 170 MPa and the compression strength 400MPa. Granules 2-4mm in diameter were implanted during operations. The amount of the glass-ceramic used ranged from 5 to 45 g. β-tricalcium phosphate (Poresorb ® , Lasak Ltd., Prague, Czech Republic) in granule form with particle size of 0,6 to 2 mm was implanted. The porosity of the interconnectedtricalcium phosphate scaffold was 35±5 %, the average macropore size was 100 μm in diameter, the size of micropores was 1-5 μm, and the sintering temperature was 1180°C. The quantity of implanted β-tricalcium phosphate ranged from 3 to 66 g.
Clinical and radiographic follow-up
Clinical and radiographic examinations of all patients were carried out at 3-12 years (7 years on average) after implantation of the bioactive glass-ceramic and at 2-8 years (4 years on average) after implantation of tricalcium phosphate. The clinical follow-up included subjective complaints, objective findings focused on soft tissue status in the area of synthetic bone graft substitute filling, range of movement in adjacent joints and weight-bearing ability of the treated extremity. The radiographs were taken in standard projections and evaluated independently by three investigators. The results were then compared for inter-observer agreement and, in case of differences, the patient´s radiograph was reviewed by all three observers together. The radiographic integration of bioactive glass-ceramic was evaluated according to the criteria of Uchida et al. [16] to determine the presence of the markedly seen bridging trabeculae at the recipient bone-implant interface and the amount of incorporation of glass-ceramic. The radiographic integration of tricalcium phosphate was classiffied according to the criteria of Nigro and Grace [17] . Complete integration was associated with radiographical homogeneity of host bone and bone graft substitute, and trabecular remodelling was seen. Integration was judged to be partial when the formation of a partial gap between synthetic bone graft substitute and host bone was observed. Resorption was defined as gradually decreased radiopacity of the bone graft substitute until complete resorption.
Results
AW glass-ceramic
The clinical evaluation showed that 10 patients had no subjective complaints, 4 reported transient pain, 3 had pain at activity, 2 reported pain during weather changes, 1 woman observed pain during pregnancy, and 1 patient had pain at rest. No restriction in weightbearing of the limb treated was reported by any of the patients. Radiographs obtained immediately after surgery showed radiolucent zones between the implanted glassceramic and the surrounding bone. Periodic assessments revealed that, during the period of 3-4.5 months, the radiolucent zones faded and new bone developed. Continuing radiographic observations up to a maximum of 12 years after implantation have shown no evidence of biodegradation of the apatite-wollastonite glass-ceramic material. The distinct bridging bone trabeculae bound to the surface of glass-ceramic granules were observed in all patients (Fig. 1 ). In the metaphyseal region of long bones, the incorporated glass-ceramic granules still remained distinct and seemed to be connected to each other. However, in the diaphyseal region of long bones, there was little distinction between the glass-ceramic granules and adjacent bone. Increased bone density around the incorporated glass-ceramic material with remodeling of the cortex in the diaphyseal region of long bones was found in six of the nine patients. No degenerative changes were encountered in adjacent joints. No postoperative infections or fractures were observed in our patients. Recurrence of bone cysts was identified in one case. The patient had further curettage of recurrence located in the area surrounding an incorporated glass-ceramic material and the cavity was filled with allogeneic cancellous bone grafts; this patient had no pain. One male with a small residual defect required no further surgery. period necessary for disappearance of these radiolucent zones was 9 weeks (range 5-13 weeks). Periodic radiographic assessments revealed decreased radiographic density of βtricalcium phosphate and replacement of β-tricalcium phosphate granules by newly formed bone trabeculae. These processes apper to have started on the periphery of the synthetic filling and progressed centrally. Signs of the implanted β-tricalcium phosphate still remained radiographically at the final follow-up in all 18 cases, but the material was incorporated in the surrounding bone and gradually resorbed. Postoperative fractures were recorded in two patients with a unicameral bone cyst in the humerus. One male fell 3 weeks after surgery; the fracture was treated conservatively. The other male patient has had a car accident 20 months after surgery; the displaced diaphyseal fracture was treated with open reduction and plate osteosynthesis. In two young patients, growth arrest or deformity were seen before curretage of the cyst and implantation of β- were seen only in 2 cases. Both patients had further curettage of recurrence in the area surrounding an incorporated tricalcium phosphate. In the skeletaly mature male patient, the cavity was filled with autologous cancellous bone grafts; in other patient, β-tricalcium phosphate was added to the cavity at the time of repeated curettage (Fig. 2) . 
Tricalcium phosphate
Discussion
Conventional bone grafting with an autologous bone harvested from the iliac crest is the current gold standard because the autografts contain marrow cells including nondifferentiated mesenchymal stem cells, osteogenic bone cells, an osteoconductive matrix and osteoinductive proteins. However, the availability of autologous bone grafts is limited, their harvesting requires a further operation with prolonged operative time and is often associated with donor-site morbidity. The processed allograft bone is an attractive alternative to the autologous bone [18] . These allogeneic bone grafts are primarily osteoconductive, but they retain a variable number of osteoinductive proteins. The host immune response to freezedried allografts is less vigorous than the response to fresh or fresh-frozen allografts [19] . The transmission of infectious agents from donor to recipient with allogeneic bone grafts is their major risk and a loss of mechanical properties is their important disadvantage. The infectious risk is increased when fresh allografts are used and, therefore, serological testing has to be performed to reduce that risk.
In an effort to overcome limitations of autografts and allografts, the synthetic bone graft substitutes were developed from a variety of materials, including calcium phosphates,
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important role than their size that is modified during degradation of resorbable bioceramics, whereas the sizes and the densities are equally important in unresorbable biomaterials [2, 27] .
Although tricalcium phosphate was incorporated in the surrounding bone and gradually resorbed, signs of the implanted β-tricalcium phosphate still remained radiographically in all cases. In our opinion, the implanted quantity of tricalcium phosphate was higher in our patients compared to other authors [5] [6] [7] 15] . More experimental and clinical studies will be required in order to resolve the healing problems of large bone defects combining scaffolds with osteoinductive factors and cell cultures. According to this study, interconnectedtricalcium phosphate produced better clinical results than apatite-wollastonite glassceramic. Interconnected -tricalcium phosphate is a successful and safe bone graft substitute for the treatment of benign bone tumours and tumour-like lesions because of its biocompatibility and bioresorbability. 
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